For those who are new to CTIX, a unique feature of

For those who are new to CTIX, a unique feature of this company is that not only does it have a new approach to cancer treatment (Kevetrin, currently starting human trials), but as an "insurance policy" it has a second drug rapidly approaching human trials -- Prurisol. Prurisol is an effective treatment (I hesitate to say "cure" but it seems as if it might be) for psoriasis. Psoriasis is not only a common and uncomfortable, unsightly skin condition, but often is associated with a form of rheumatoid arthritis, psoriatic arthritis. Although the company has made NO claims in regards to other possible uses of Prurisol (should if prove effective in humans against psoriasis), we have speculated that if it is effective against an auto-immune disease like psoriasis, it might be effective against other auto-immune diseases as well. There are about 100 different syndromes lumped into the category of "rheumatoid arthritis" -- so perhaps those might be a target, as well as non-rheumatoid auto-immune diseases.

We have used the example of MDVN to illustrate the value of having a second drug in the pipeline as "insurance." When MDVN's flagship drug failed, its stock price was cut in half in a matter of minutes. Now, it is trading at 5 times those levels, because of the seeming success of another drug. It is quite amazing for a company the size of CTIX to have an "insurance policy" 2nd drug rapidly heading toward human trials, and there are other potential drugs in the company's intellectual property portfolio.